Wang Li
Department of Hematology, The 923th Hospital of the People's Liberation Army of China, Nanning 530021, Guangxi Zhuang Autonomous Region, China E-mail: wl923yy@ 163.com.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):629-632. doi: 10.19746/j.cnki.issn1009-2137.2019.02.052.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used in the treatment of hematological diseases, HLA incompatibility is displayed in most cases. Some patients have prestored donor-specific antibodies (DSA) or new emerging antibodies after transplantation. Donor-specific antibodies may cause graft failure and poor graft function ,and affect transplant outcome. It is important to identify high risk candidates, assay antibodies and give proper intervention for improving the outcome of allo-HSCT. In this review, the research progress of DSA in allo-HSCT is summarized, including DSA prevalence, risk factors, the role of prestored DSA in unrelated and haploidentcal HSCT, the effect of donor derived antibodies in transplantation and desensitization therapy.
